CD44 and cancer: While Gal-3 expression has been associated with CSC characteristics in various cancer types, a study by Ilmer et al. showed that Gal-3− breast CSCs are highly tumorigenic, exhibit a mesenchymal phenotype, and show increased drug resistance with an enrichment of CSC markers (CD24−/CD44+).